Mulado Prolong (Metformin Hydrochloride)

Metformin Hydrochloride, the active ingredient in Mulado Prolong, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Mulado Prolong as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is used in the management of disorders affecting glucose metabolism, primarily type 2 diabetes mellitus. - Type 2 diabetes mellitus: Improves glycemic control by lowering fasting and post‑prandial blood glucose levels.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzymes. - Vitamin B12 deficiency: may develop with long‑term use.

Metformin Hydrochloride requires careful assessment of patient factors and monitoring to minimize risks. - Renal function assessment: evaluate eGFR before initiating and periodically thereafter. - Lactic acidosis risk: avoid in patients with significant renal or hepatic impairment. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal dysfunction. - Cimetidine: increases metformin plasma concentrations. - Alcohol: heightens risk of lactic acidosis. - Renally toxic drugs (e.g., NSAIDs): may impair metformin clearance.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Thiazide diuretics: can attenuate glucose‑lowering effect. - ACE inhibitors: require monitoring of renal function.